Abstract 5949
Background
In hereditary cancers, disclosure of genetic testing and communication of genetic information to family members is crucial to manage their potential cancer risk. In Switzerland, according to privacy law, genetic information can be passed on to at-risk relatives only through the individual identified with the pathogenic mutation but 20-40% of at-risk family members remain unaware of relevant genetic information and less than 50% refer to genetic services. Healthcare providers have a relevant and challenging role in supporting family communication on genetics but this is still limited and not clear. The aim of the study is to explore how mutation carriers’ communicate about genetics within family members and how this is concretely supported in clinical practice.
Methods
Ongoing qualitative study. Data are collected with distinct focus groups with a purposeful sample of about 30 hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) mutation carriers and 30 relatives from three linguistic areas of Switzerland. The sample is diversified in terms of gender, clinical history and attitude towards family communication. Interviews with 15 healthcare providers routinely involved in genetic counselling are performed, too. Data collection and data analysis continue iteratively until data saturation according to constant comparative method.
Results
Qualitative data from focus groups and interviews show that family communication of genetic information is complex, affected by a wide variety of factors and closely interconnected with the disease condition. Communication to family members takes place according to different patterns and changes along the trajectory of life and illness. Healthcare providers play an important role.
Conclusions
Supporting communication of genetic information within family members is a challenging aspect of genetic healthcare and risk communication. Research about communication on genetics is timely and essential to implement interventions that can enhance cascade testing and genetic information for cancer prevention and control in clinical practice and for multilevel public health initiatives.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2108 - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3090 - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01
Presenter: Daniele Raggi
Session: Poster Display session 3
Resources:
Abstract
5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
Presenter: Albert Font
Session: Poster Display session 3
Resources:
Abstract
3206 - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
Presenter: Scott Tagawa
Session: Poster Display session 3
Resources:
Abstract
3110 - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
Presenter: Florian Roghmann
Session: Poster Display session 3
Resources:
Abstract
3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Presenter: Jean-Michel Lavoie
Session: Poster Display session 3
Resources:
Abstract
2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)
Presenter: Markus Eckstein
Session: Poster Display session 3
Resources:
Abstract
2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival
Presenter: Elise Nassif
Session: Poster Display session 3
Resources:
Abstract
2835 - Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Presenter: David Sarid
Session: Poster Display session 3
Resources:
Abstract
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract